How T cells can be enhanced to fight tumors more effectively
Official title: Mechanisms of Durable Antitumor Immunity Mediated by PI3K-targeted T cells
Funded at Emory University · NIH-11124057 · Data updated 2026-11-12
This study is looking at how a special drug can help boost the power of your immune cells, called T cells, so they can better fight solid tumors in cancer patients, with the hope of making treatments more effective and lasting.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | June 7, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $632,039 |
| NIH project number | 5R01CA275199-03 |
| Project ID | NIH-11124057 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with solid tumors who may benefit from enhanced adoptive cell therapies.
✕Less likely to help
Patients with non-solid tumors or those who do not qualify for adoptive cell therapy may not receive benefits from this research.
What this research studies
This research investigates how modifying the metabolism of T cells can improve their ability to combat solid tumors. By using a specific drug, CAL-101, the team aims to enhance the effectiveness and durability of tumor-targeted T cells when administered to patients. The study focuses on understanding the mechanisms that allow these modified T cells to persist longer in the body and mount stronger responses against tumors. The findings could lead to more effective adoptive cell therapies for cancer patients.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that harness the body's immune system to fight tumors.
How similar studies have gone: Other research has shown promise in enhancing T cell responses through metabolic modifications, suggesting a potential for success in this approach.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Paulos, Chrystal Mary — Emory University
- Study coordinator: Paulos, Chrystal Mary
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.